AstraZeneca GmbH

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate

AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment ... more

AstraZeneca starts collaboration with start-up BenevolentAI

AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). Scientists from the two organisations will work ... more

Bachem renews supply contract with AstraZeneca

The Bachem Group announced the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin. The extended partnership enhances the cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active subs ... more

AstraZeneca PLC

We discover new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. We also focus on getting the bes ... more

AstraZeneca AG

We are a global, innovative biopharmaceutical company that specializes in the research, development, manufacture and marketing of prescription pharmaceuticals. AstraZeneca makes an important contribution to the health of patients. more

AstraZeneca Argentina S.A.

As one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare. more